Adaptive (ADPT) Q3 2026 Earnings Call Transcript
Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.
How this was made

The 30-second read
Why it matters
The guidance lift reflects robust demand for clonoSEQ testing, likely supporting the stock price in the short term.
Market read
Guidance raise after strong Q3 results is a material catalyst for Adaptive and its sector.
What to watch
Potential delays in payer coverage expansions could limit revenue upside.
Background
Adaptive (ADPT) provided its Q3 2026 earnings call, highlighting strong volume growth, a $270 M backlog, and raised full‑year MRD revenue guidance.
Ticker impact
Adaptive raised its full‑year 2026 MRD revenue guidance after reporting 46% YoY clinical volume growth and a $270 M backlog.
upward pressure as investors price in stronger revenue outlook
The company disclosed higher clinical testing volumes and a sizable backlog, prompting an upward revision of full‑year revenue guidance, which typically lifts the share price.
Market effects
Boosts outlook for the molecular diagnostics and precision oncology sector.
Positive for U.S. biotech investors.
May influence global MRD testing market sentiment.
Counterpoint
If reimbursement pressures intensify, the guidance raise may be premature.
Key entities
- CompanyAdaptive
US‑listed biotech focused on MRD testing.


